Nencki Institute and Pikralida Sp. z o. o. collaborate on „Use of matrix metalloproteinase inhibitor to develop an innovative therapy of preventing the development of post-traumatic and post-stroke epilepsy” project, which is cofunded by the European Funds.

The aim of the project is to develop an innovative therapeutic method for preventing post-traumatic and post-stroke epileptic seizures by modulating matrix metalloproteinase 9 (MMP-9) activity. Tasks include i.a. development of the API and investigational medicinal product manufacturing technology, evaluation of MMP-9 inhibitor therapeutic potential in animal models, performing preclinical and phase I clinical trials. Laboratory of Neurobiology led by professor Leszek Kaczmarek will commence work on behalf of the Institute.

Project no POIR.01.01.01-00-0235/20 is co-funded by the European Union under the Smart Growth Operational Programme 2014-2020, Priority axis I “Support for R&D activity of enterprises”, Submeasure 1.1.1 Industrial research and development work implemented by enterprises, within the “3 / 1.1.1 / 2020 Fast track for Mazovia” funding scheme by the National Center for Research and Development.